Dmytro Fedkov

Dr. Dmytro Fedkov

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2020 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
SCStanley Cohen
Stanley Cohen
KTKatie Tuckwell
Katie Tuckwell
TKTamiko R. Katsumoto
Tamiko R. Katsumoto
RZRui Zhao
Rui Zhao
JGJoshua Galanter
Joshua Galanter
MGMark C. Genovese
Mark C. Genovese
Objective: To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of Bruton's tyrosine kinase (BTK), in patients with active rheumatoid arthritis (RA).Methods: Patients with RA and an inadequate response to methotrexate (MTX) (cohort 1; n = 480) were randomized to receive fenebrutinib (50 mg once daily, 150 mg once daily, or 200 mg twice daily), adalimumab (40 mg every other week), or placebo. Patients with RA and an inadequate response to tumor necrosis factor inhibitors (cohort 2; n = 98) received fenebrutinib (200 mg twice daily) or placebo. Both cohorts continued MTX therapy.Results: In cohort 1, the percentages of patients in whom American College of Rheumatology 50% improvement criteria (ACR50) was achieved at week 12 were similar in the fenebrutinib 50 mg once daily and placebo groups, and were higher in the fenebrutinib 150 mg once daily group (28%) and 200 mg twice daily group (35%) than in the placebo group (15%) (P = 0.016 and P = 0.0003, respectively). Fenebrutinib 200 mg twice daily and adalimumab (36%) were comparable (P = 0.81). In cohort 2, ACR50 was achieved in more patients receiving fenebrutinib 200 mg twice daily (25%) than placebo (12%) (P = 0.072). The most common adverse events in the fenebrutinib groups included nausea, headache, anemia, and upper respiratory tract infections. Fenebrutinib had significant effects on myeloid and B cell biomarkers (CCL4 and rheumatoid factor). Fenebrutinib and adalimumab caused overlapping as well as distinct changes in B cell and myeloid biomarkers.Conclusion: Fenebrutinib demonstrates efficacy comparable to adalimumab in patients with an inadequate response to MTX, and safety consistent with existing immunomodulatory therapies for RA. These data support targeting both B and myeloid cells via this novel mechanism for potential efficacy in the treatment of RA.

16 September 2022 in Rheumatology International
Verified
Journal Article
Open access
PDF file
DFDmytro Fedkov
Dmytro Fedkov
ABAndrea Berghofen
Andrea Berghofen
CWChristel Weiss
Christel Weiss
CPChristine Peine
Christine Peine
FLFelix Lang
Felix Lang
JLJan Leipe
Jan Leipe
EULAR highlighted the essential role of digital health in increasing self-management and improving clinical outcomes in patients with arthritis. The objective of this study was to evaluate the efficacy and safety of the digital health application (DHA) in patients with inflammatory arthritis. We assessed demographic parameters, treatment regimen, disease activity, and other patient-reported outcomes at baseline and after 4 weeks of DHA use added to standard care treatment. Of 17 patients, who completed the study, 7 (41.2%) patients were male, ranging from 19 to 63 (40.5 ± 12.2) years. No significant change in antirheumatic treatment was observed during the study. Statistically significant improvements (p < 0.05) were noted for health-related quality of life (increase in Physical Component Summary of Short Form-36 (SF-36) by 23.6%) and disease activity (decrease of Clinical Disease Activity Index and Simple Disease Activity Index by 38.4% and 39.9%, respectively). Clinically significant improvement was demonstrated for SF-36 Total Score (+ 14.4%), disease activity (Rheumatoid Arthritis Disease Activity Index− 5 to 15.9%), and depression (Patient Health Questionnaire− 9 to 13.5%). None of the efficacy parameters showed negative trends. No adverse events were reported throughout the study. The usability level was high i.e., the mean mHealth Application Usability Questionnaire Score of 5.96 (max.: 7.0) demonstrated a high level of application usability. This suggests that using a personalized disease management program based on DHA significantly improves several measures of patient-reported outcomes and disease activity in patients with inflammatory arthritis in a timely manner. These findings highlight the potential of complementary digital therapy in patients with inflammatory arthritis.

14 May 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
TKTürker Kurt
Türker Kurt
DVDiana Vossen
Diana Vossen
FSFalk Schumacher
Falk Schumacher
JSJohannes Strunk
Johannes Strunk
DFDmytro Fedkov
Dmytro Fedkov
SVStefan Vordenbäumen
Stefan Vordenbäumen
Background: Mobile applications (apps) are a resource for information on lifestyle and nutrition which are associated to improved outcomes in inflammatory arthritis. Objective: The aim of this study was to explore whether targeted lifestyle counselling via an app improves disease activity in arthritis patients. Methods: Patients with rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA) were randomized to 12 weeks of lifestyle counselling via an app (Mida, Midaia GmbH, Germany) pertaining to a healthy Mediterranean Diet, physical activity, and mental health. Disease activity was measured with specific instruments by a blinded physician and categorized (remission, low, moderate, high). Dietary adherence was assessed by the Mediterranean Diet Adherence Screener (MEDAS). Mixed effects logistic regression adjusted to baseline disease activity, age, and sex were calculated. Results: Of 158 patients included (73% female, 53.3 ± 11.7 years), 74 were in the active counselling group (ACG). All showed improvement in low disease activity or remission. ACG patients had an odds ratio (OR) of 2.8 (95%-CI 1.1–7.2, p = 0.035), while OR in the control group was not significant OR = 2.1 (0.9–5.0, p = 0.097). The control group was less likely to reach a MEDAS >= 4 (OR = 0.16 (0.03–0.77), p = 0.02), while this was not seen in the ACG (OR = 0.54 (0.06–4.63), p = 0.6). Patients in the ACG showed a tendency towards improved adhesion to a Mediterranean Diet (MEDAS) (β = 0.35 (−0.05–0.74), p = 0.086). This tendency was not observed in the control group (β = 0.09 (−0.29–0.46), p = 0.64). Conclusions: Individualized lifestyle and dietary counselling via app may help to improve disease control in inflammatory arthritis patients.

22 June 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
OIOleg Iaremenko
Oleg Iaremenko
LPLiubov Petelytska
Liubov Petelytska
ODOlena Dyadyk
Olena Dyadyk
NNNataliia Negria
Nataliia Negria
DFDmytro Fedkov
Dmytro Fedkov

26 September 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
OIOleg Iaremenko
Oleg Iaremenko
ISIuliia Shynkaruk
Iuliia Shynkaruk
DFDmytro Fedkov
Dmytro Fedkov
KIKateryna Iaremenko
Kateryna Iaremenko
LPLiubov Petelytska
Liubov Petelytska

10 April 2026 in Rheumatology International
Verified
Journal Article
Open access
PDF file
DFDmytro Fedkov
Dmytro Fedkov
DYDanylo Yevstifeiev
Danylo Yevstifeiev
OIOleg Iaremenko
Oleg Iaremenko
DKDaria Koliadenko
Daria Koliadenko
LPLiubov Petelytska
Liubov Petelytska
SVStefan Vordenbäumen
Stefan Vordenbäumen
Despite advances in pharmacotherapy, many patients with inflammatory arthritis (IA) experience residual pain even in remission. Digital health applications (DHAs), when combined with machine learning, may help identify predictors of pain relief in real-world care. To identify predictors of clinically meaningful pain relief in IA using DHA data. We retrospectively analyzed 914 adults with rheumatoid arthritis, psoriatic arthritis, or spondyloarthritis using the Mida Rheuma App. Patients were categorized according to sufficient pain relief, defined as ≥ 30% reduction in pain intensity (visual analogue scale, 0–100) at 12 weeks. Candidate predictors for pain relief included baseline demographics, diagnosis, disease duration, and psychosocial and lifestyle factors: fatigue (Brief Fatigue Inventory, BFI), psychological distress (Patient Health Questionnaire, PHQ-4), sleep and diet quality, physical activity, social support, and app engagement. Multivariable logistic regression and Random Forest models were fitted; non-linear effects were explored using Shapley Additive Explanations. 25.4% of patients achieved ≥ 30% pain reduction. Higher baseline pain intensity was the strongest predictor of response (adjusted odds ratio [OR] 1.59). Fatigue reduced the likelihood of improvement (BFI OR = 0.71), with a SHAP-defined threshold of BFI > 6. Better sleep quality was associated with an increased likelihood of response (OR = 1.23). In exploratory SHAP analyses, the decline in response probability was steepest above BFI of approximately 6. Model discrimination was modest (receiver operating characteristic area under the curve ≈0.61). In IA, pain relief in digital care is associated with baseline pain severity, fatigue, and sleep quality. These findings should be interpreted as hypothesis-generating and require external validation before clinical application.